The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Home | Diabesity WG

Diabesity WG


10 / 14 results found

{%SMALL_TITLE%}
{%SUMMARY_INFO%}

{%BOTTOM_TEXT%}

{%SMALL_TITLE%}

{%EXCERPT%}

{%BOTTOM_TEXT%}

Speaker
Esteban Porrini, Spain

Panellists
Anette Tønnes Pedersen, Denmark
Ana Rodríguez, Spain

Moderator
Morten Buus Jørgensen, Denmark

 

Diabesity WG